Literature DB >> 32640274

SARS-CoV2 envelope protein: Non-synonymous mutations and its consequences.

Sk Sarif Hassan1, Pabitra Pal Choudhury2, Bidyut Roy3.   

Abstract

In the NCBI database, as on June 6, 2020, total number of available complete genome sequences of SARS-CoV2 across the world is 3617. The envelope protein of SARS-CoV2 possesses several non-synonymous mutations over the transmembrane domain and (C)-terminus in 15 (0.414%) genomes among 3617 available SARS-CoV2 genomes. More precisely, it is to be mentioned that 10(0.386%) out of 2588 genomes from the USA, 3(0.806%) from Asia, 1 (0.348%) from Europe and 1 (0.274%) from Oceania contain the missense mutations over the envelope proteins of SARS-CoV2 genomes. The C-terminus motif DLLV has been changed to DFLV and YLLV in the proteins QJR88103 (Australia: Victoria) and QKI36831 (China: Guangzhou) respectively, which might affect the binding of this motif with the host protein PALS1.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  COVID-19; Envelope protein; Non-synonymous mutations; SARS-CoV2

Year:  2020        PMID: 32640274      PMCID: PMC7335631          DOI: 10.1016/j.ygeno.2020.07.001

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


Introduction

The present pandemic situation of the Severe Acute Respiratory Syndrome (COVID-19) is caused by the RNA virus SARS-CoV2 which is characterized by its rapid mutations up to a million times higher than that of their hosts [1]. Several mutations have been detected in various proteins of the SARS-CoV2 over a short period of time, which are recently reported in various articles [[2], [3], [4]]. Genomic variations and evolution enabled the virus to escape host immunity [5,6]. So, such variability would help the scientists towards the drug development [1]. Among various proteins of SARS-CoV2, spike(S), envelope (E), membrane(M) and nucleocapsid (N) are the four structural proteins which help them in assembling and releasing new copies of the virus within human cell [7]. The CoV envelope (E) protein is the smallest among the four structural proteins involved in several aspects of the virus life cycle, such as assembly, budding, envelope formation, and pathogenesis [7]. However, the molecular mechanism involving E-protein in pathogenesis is not yet clearly understood. Notably, this protein interacts with other structural proteins such as membrane(M) and other accessory proteins viz. ORF3a, ORF7a and host cell proteins [8]. Envelope protein of SARS-CoV2 is 76 amino acids long and possesses three important domains viz. (N)-terminus, transmembrane domain (TMD) and (C)-terminus (Fig. 1 ). The (C)-terminal domain of envelope protein in SARS-CoV2 binds to human PALS1, a tight junction-associated protein, which is essential for the establishment and maintenance of epithelial polarity in mammals [9,10].
Fig. 1

Amino acid sequence and domains of the envelope protein of SARS-CoV2 [7].

Red and blue colors are representing hydrophobic and hydrophilic amino acid, respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Amino acid sequence and domains of the envelope protein of SARS-CoV2 [7]. Red and blue colors are representing hydrophobic and hydrophilic amino acid, respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Four mutations including one deletion have been found in the envelope protein of SARS-CoV2 with reference to the SARS-CoV1, a species of coronavirus that also infects humans, bats and certain other mammals. The alignment of the envelope proteins of the SARS-CoV1 and SARS-CoV2 is given in Fig. 2 .
Fig. 2

Clustal alignment of the envelope protein of SARS-CoV1 and SARS-CoV2.

Mutations in (C)-terminus domain in the E protein protein of SARS-CoV2 are T55S, V56F, E69R (the mutation of an amino acid A1 to an amino acid A2 is denoted by A1pA2 where p denotes location in the reference amino acid sequence).The deletion mutation of G at the 70th position with respect to the reference envelope protein of SARS-CoV1 is also noted.

Clustal alignment of the envelope protein of SARS-CoV1 and SARS-CoV2. Mutations in (C)-terminus domain in the E protein protein of SARS-CoV2 are T55S, V56F, E69R (the mutation of an amino acid A1 to an amino acid A2 is denoted by A1pA2 where p denotes location in the reference amino acid sequence).The deletion mutation of G at the 70th position with respect to the reference envelope protein of SARS-CoV1 is also noted. It is reported that the C-terminus domain of the envelope protein contains the motif DLLV which binds to the host cell PALS1 protein to facilitate infection [9,11,12]. In this present study, non-synonymous mutations over the envelope protein of SARS-CoV2 across the available 3617 SARS-CoV2 genomes (as on 6th June 2020), have been found and accordingly their probable consequences are discussed.

Methods

From the NCBI virus database, all the protein sequences of 3617 SARS-CoV2 genomes were fetched. Then the amino acid sequences of envelope protein of SARS-CoV2 are exported in fasta format using file operations through Matlab. These sequences (fasta formatted) are blasted using Clustal-Omega and found the mismatched and from their mutations and their associated positions were detected [13].

Results

Among these virus genomes from 3617 patients; 2588 were from the USA, 372 were from Asia, 287 were from Europe, 365 were from Oceania and 5 were from Africa. Here, we present the non-synonymous mutations of the E-protein protein over the available 3617 SARS-CoV2 genomes (Table 1 ). It is to be noted that 10 (0.386%) out of 2588 genomes from USA, 3 (0.806%) from Asia, 1 (0.348%) from Europe and 1 (0.274%) from Oceania) contained the missense mutations (Table 1) in the envelope proteins of SARS-CoV2 genomes. Changes of the R-group of each amino acid according to the mutations are also presented (Table-1). It is to be noted that the mutation of an amino acid A 1 to an amino acid A 2 is denoted by A 1 pA 2 where p denotes location in the reference amino acid sequence.
Table 1

Non- synonymous mutation in the E-protein of SARS-CoV2.

Protein-IDGeo-locationMutationDomainChange of R-group
QJA42107USA: VAA36VTMDaHydrophobic to Hydrophobic
QJQ84222USA: KENNER, LAL26FTMDHydrophobic to Hydrophobic
QHZ00381South KoreaL37HTMDHydrophobic to Hydrophilic
QJS53352Greece: AthensL39MTMDHydrophobic to Hydrophobic
QJR88103Australia: VictoriaL73FC-terminusHydrophobic to Hydrophobic
QKE45838USA: CAP71LC-terminusHydrophobic to Hydrophobic
QKE45886USA: CAP71LC-terminusHydrophobic to Hydrophobic
QKE45898USA: CAP71LC-terminusHydrophobic to Hydrophobic
QKE45910USA: CAP71LC-terminusHydrophobic to Hydrophobic
QJE38284USA: CAP71LC-terminusHydrophobic to Hydrophobic
QIU81527USA: WAP71LC-terminusHydrophobic to Hydrophobic
QKG87268USA: MassachusettsS68FC-terminusHydrophobic to Hydrophobic
QKG88576USA: MassachusettsS68FC-terminusHydrophobic to Hydrophobic
QKI36831China: GuangzhouD72YC-terminusHydrophilic to Hydrophobic
QKI36855China: GuangzhouS68CC-terminusHydrophilic to Hydrophobic

TMD: transmembrane domain.

In less than 0.5% of the SARS-CoV2 genomes, the E-protein possesses the missense mutations as adumbrated in the Table 1. In TMD and C-terminus domain, there are nine different mutations where the R-group property changes. But only in QHZ00381, for the mutation L37H in the TMD of the envelope protein causes changes in amino acid from hydrophobic to hydrophilic. TMD was also observed to be conserved over the SARS-CoV1 and COV2 genomes, but the protein sequences of QJA42107 (USA: VA), QJQ84222(USA: KENNER, LA), QHZ00381(South Korea) and QJS53352(Greece: Athens) possess four mutations A36V, L26F, L37H and L39M, respectively, in the TMD of the envelope protein. Change in the R-group property from Hydrophobic to Hydrophilic in the TMD of the envelope protein of the virus from South Korea may affect the ion channel activity of the envelope protein. The motif ′DLLV′ has been changed to ′DFLV′ and ′YLLV′ in the proteins QJR88103 (Australia: Victoria) and QKI36831 (China: Guangzhou) due to the mutations L73F and D72Y respectively. These mutations having changes in the motif ′DFLV′ may mis-target the PALS1 at Golgi and delaying TJ formation and accordingly may influence replication and/or infectivity of the virus [10]. In the C-terminus domain of the E-protein of SARS-CoV2 the amino acid S at 68th position changes to the amino acids F and C in the proteins {QKG87268,  QKG88576} from the USA: Massachusetts and QKI36855 from China: Guangzhou respectively. Note that the mutation of the amino acid S to F keeps the R-group property unchanged (i.e. hydrophobic to hydrophilic) while that of the amino acid S to C changes the R-group from Hydrophilic to Hydrophobic. This would possibly make changes in protein functions and interactions. Non- synonymous mutation in the E-protein of SARS-CoV2. TMD: transmembrane domain.

Concluding remarks

Among all the proteins present in the novel RNA virus, some accessory proteins such as ORF6, ORF7b, ORF8, ORF10 contain the least number of missense mutation as reported in various studies [[14], [15], [16]]. And same is true for E-protein. We find 15 among 3617 (0.414%) of the SARS-CoV2 genome contains eight different types of mutations in TMD and C-terminus of the envelope protein. Mutated E-protein might affect replication and propagation of the SARS-CoV2 as has been observed in cases of SARS-CoV and MERS-CoV in mouse model [17]. Potential studies have also shown that vaccine against the E-protein mutated viruses can reduce the infectivity in mouse model.

Author contributions

SH conceived the problem and examined the mutations. SH, PPC, BR analyzed the data and result. SH wrote the initial draft which was checked and edited by all other authors to generate the final version.

Declaration of Competing Interest

The authors do not have any conflicts of interest to declare.
  13 in total

Review 1.  Emerging Themes in PDZ Domain Signaling: Structure, Function, and Inhibition.

Authors:  Xu Liu; Ernesto J Fuentes
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-28       Impact factor: 6.813

2.  The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis.

Authors:  Kim-Tat Teoh; Yu-Lam Siu; Wing-Lim Chan; Marc A Schlüter; Chia-Jen Liu; J S Malik Peiris; Roberto Bruzzone; Benjamin Margolis; Béatrice Nal
Journal:  Mol Biol Cell       Date:  2010-09-22       Impact factor: 4.138

3.  Genetic lesions within the 3a gene of SARS-CoV.

Authors:  Timothy H P Tan; Timothy Barkham; Burtram C Fielding; Chih-Fong Chou; Shuo Shen; Seng Gee Lim; Wanjin Hong; Yee-Joo Tan
Journal:  Virol J       Date:  2005-06-20       Impact factor: 4.099

4.  Missense mutations in SARS-CoV2 genomes from Indian patients.

Authors:  Sk Sarif Hassan; Pabitra Pal Choudhury; Bidyut Roy; Siddhartha Sankar Jana
Journal:  Genomics       Date:  2020-08-18       Impact factor: 5.736

Review 5.  Coronavirus envelope protein: current knowledge.

Authors:  Dewald Schoeman; Burtram C Fielding
Journal:  Virol J       Date:  2019-05-27       Impact factor: 4.099

6.  Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant.

Authors:  Maria Pachetti; Bruna Marini; Francesca Benedetti; Fabiola Giudici; Elisabetta Mauro; Paola Storici; Claudio Masciovecchio; Silvia Angeletti; Massimo Ciccozzi; Robert C Gallo; Davide Zella; Rudy Ippodrino
Journal:  J Transl Med       Date:  2020-04-22       Impact factor: 5.531

7.  Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice.

Authors:  Marta L Dediego; Lecia Pewe; Enrique Alvarez; Maria Teresa Rejas; Stanley Perlman; Luis Enjuanes
Journal:  Virology       Date:  2008-05-02       Impact factor: 3.616

Review 8.  The coronavirus nucleocapsid is a multifunctional protein.

Authors:  Ruth McBride; Marjorie van Zyl; Burtram C Fielding
Journal:  Viruses       Date:  2014-08-07       Impact factor: 5.048

9.  Molecular conservation and differential mutation on ORF3a gene in Indian SARS-CoV2 genomes.

Authors:  Sk Sarif Hassan; Pabitra Pal Choudhury; Pallab Basu; Siddhartha Sankar Jana
Journal:  Genomics       Date:  2020-06-12       Impact factor: 5.736

10.  Severe acute respiratory syndrome coronavirus accessory protein 9b is a virion-associated protein.

Authors:  Ke Xu; Bo-Jian Zheng; Rong Zeng; Wei Lu; Yong-Ping Lin; Liang Xue; Li Li; Lei-Lei Yang; Chen Xu; Jie Dai; Fei Wang; Qing Li; Qing-Xi Dong; Rui-Fu Yang; Jia-Rui Wu; Bing Sun
Journal:  Virology       Date:  2009-04-25       Impact factor: 3.616

View more
  13 in total

1.  Whole genome analysis of more than 10 000 SARS-CoV-2 virus unveils global genetic diversity and target region of NSP6.

Authors:  Indrajit Saha; Nimisha Ghosh; Ayan Pradhan; Nikhil Sharma; Debasree Maity; Kaushik Mitra
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

2.  The evolving proteome of SARS-CoV-2 predominantly uses mutation combination strategy for survival.

Authors:  L Ponoop Prasad Patro; Chakkarai Sathyaseelan; Patil Pranita Uttamrao; Thenmalarchelvi Rathinavelan
Journal:  Comput Struct Biotechnol J       Date:  2021-06-05       Impact factor: 7.271

3.  Missense mutations in SARS-CoV2 genomes from Indian patients.

Authors:  Sk Sarif Hassan; Pabitra Pal Choudhury; Bidyut Roy; Siddhartha Sankar Jana
Journal:  Genomics       Date:  2020-08-18       Impact factor: 5.736

4.  A unique view of SARS-CoV-2 through the lens of ORF8 protein.

Authors:  Sk Sarif Hassan; Alaa A A Aljabali; Pritam Kumar Panda; Shinjini Ghosh; Diksha Attrish; Pabitra Pal Choudhury; Murat Seyran; Damiano Pizzol; Parise Adadi; Tarek Mohamed Abd El-Aziz; Antonio Soares; Ramesh Kandimalla; Kenneth Lundstrom; Amos Lal; Gajendra Kumar Azad; Vladimir N Uversky; Samendra P Sherchan; Wagner Baetas-da-Cruz; Bruce D Uhal; Nima Rezaei; Gaurav Chauhan; Debmalya Barh; Elrashdy M Redwan; Guy W Dayhoff; Nicolas G Bazan; Ángel Serrano-Aroca; Amr El-Demerdash; Yogendra K Mishra; Giorgio Palu; Kazuo Takayama; Adam M Brufsky; Murtaza M Tambuwala
Journal:  Comput Biol Med       Date:  2021-04-15       Impact factor: 6.698

5.  Interactions of Severe Acute Respiratory Syndrome Coronavirus 2 Protein E With Cell Junctions and Polarity PSD-95/Dlg/ZO-1-Containing Proteins.

Authors:  Yanlei Zhu; Flavio Alvarez; Nicolas Wolff; Ariel Mechaly; Sébastien Brûlé; Benoit Neitthoffer; Sandrine Etienne-Manneville; Ahmed Haouz; Batiste Boëda; Célia Caillet-Saguy
Journal:  Front Microbiol       Date:  2022-02-23       Impact factor: 5.640

6.  The First Molecular Characterization of Serbian SARS-CoV-2 Isolates From a Unique Early Second Wave in Europe.

Authors:  Danijela Miljanovic; Ognjen Milicevic; Ana Loncar; Dzihan Abazovic; Dragana Despot; Ana Banko
Journal:  Front Microbiol       Date:  2021-06-18       Impact factor: 5.640

7.  Molecular phylogeny and missense mutations of envelope proteins across coronaviruses.

Authors:  Sk Sarif Hassan; Pabitra Pal Choudhury; Bidyut Roy
Journal:  Genomics       Date:  2020-09-11       Impact factor: 5.736

8.  Comparing the binding properties of peptides mimicking the Envelope protein of SARS-CoV and SARS-CoV-2 to the PDZ domain of the tight junction-associated PALS1 protein.

Authors:  Angelo Toto; Sana Ma; Francesca Malagrinò; Lorenzo Visconti; Livia Pagano; Kristian Stromgaard; Stefano Gianni
Journal:  Protein Sci       Date:  2020-09-08       Impact factor: 6.993

9.  SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions.

Authors:  Luis Fernando Saraiva Macedo Timmers; Julia Vasconcellos Peixoto; Rodrigo Gay Ducati; José Fernando Ruggiero Bachega; Leandro de Mattos Pereira; Rafael Andrade Caceres; Fernanda Majolo; Guilherme Liberato da Silva; Débora Bublitz Anton; Odir Antônio Dellagostin; João Antônio Pegas Henriques; Léder Leal Xavier; Márcia Inês Goettert; Stefan Laufer
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

10.  Emerging mutations in envelope protein of SARS-CoV-2 and their effect on thermodynamic properties.

Authors:  Kejie Mou; Mohnad Abdalla; Dong Qing Wei; Muhammad Tahir Khan; Madeeha Shahzad Lodhi; Doaa B Darwish; Mohamed Sharaf; Xudong Tu
Journal:  Inform Med Unlocked       Date:  2021-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.